<DOC>
	<DOCNO>NCT01964547</DOCNO>
	<brief_summary>A study compare change cognitive performance psychological status patient spasticity due Multiple Sclerosis treat Sativex placebo , add exist anti-spasticity therapy period 48 week . Secondary objective evaluate effect Sativex mood spasticity ass safety tolerability Sativex .</brief_summary>
	<brief_title>A Randomized Study Sativex Cognitive Function Mood : Multiple Sclerosis Patients</brief_title>
	<detailed_description>Eligible patient enter 50 week multicenter , double-blind , randomise , placebo-controlled , parallel group study evaluate effect Sativex cognitive performance . At scheduled clinic visit , patient assess cognitive performance , mood , severity spasticity , use investigational medicinal product number visit healthcare professional . Primary efficacy comparison make score record baseline score record end treatment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Inclusion Criteria ( ALL fulfil ) : Patient willing able give inform consent participation study . Patient age 18 year . Diagnosed disease subtype multiple sclerosis . Diagnosed symptomatic spasticity due multiple sclerosis . Patient least moderate spasticity opinion investigator . Patient fulfil least one two criterion . Subject must either : Currently establish regular dose antispasticity therapy , Previously try failed antispasticity therapy . Stable medication regimen least four week prior study entry , medication may effect spasticity and/or cognition . If patient take disease modify medication must stable dose three month prior initial visit . Willing able comply study requirement . Willing name notify responsible authority participation study , applicable . Willing allow primary care practitioner consultant , appropriate , notified participation study . Exclusion Criteria ( ANY apply ) : Any history immediate family schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . Any concomitant disease disorder ( poorly control epilepsy seizure ) may influence patient 's level cognition mood . Currently use use cannabis cannabinoidbased medication within 30 day study entry unwilling abstain duration study . Any known suspected history diagnose dependence disorder , current heavy alcohol consumption ( 60g pure alcohol per day men , 40g pure alcohol per day woman ) , current use illicit drug current nonprescribed use prescription drug . Any known suspected hypersensitivity cannabinoids excipients investigational medicinal product . Female patient child bear potential male subject whose partner child bear potential , unless willing ensure partner use effective contraception study three month thereafter . Female patient pregnant , lactate plan pregnancy course study three month thereafter . Patients receive investigational medicinal product within 12 week prior initial visit . Any significant disease disorder , opinion investigator , may either put patient risk participation study may influence result study , patient 's ability participate study . Following physical examination , patient abnormality , opinion investigator would prevent patient safe participation study . Previously randomise study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Cognition</keyword>
	<keyword>Mood</keyword>
</DOC>